This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

toujeo logo

Confidence in the positive impact of AUBAGIO® in the real-world

High treatment satisfaction scores were seen across all TSQM domains in all patients and in those who switched to AUBAGIO® (teriflunomide)1,2

Persistence is significantly better for AUBAGIO® compared to dimethyl fumarate (DMF) and injectables3

Real-world efficacy and safety of AUBAGIO® supports clinical outcomes1

No significant difference between AUBAGIO® and dimethyl fumarate (DMF) on clinical efficacy outcomes4

AUBAGIO has comparable efficacy vs.DMF (dimethyl fumarate) in the real world5,6

OFSEP* registry: Real world effectiveness of AUBAGIO vs DMF on clinical and MRI outcomes in patients with RRMS

This short video explains the results of an observational study in which teriflunomide was compared with DMF. In this study, a total number of 1770 patients with RRMS, all of which had an available brain MRI, were included in the intention to treat.

Teri-RADAR: Comparative effectiveness of AUBAGIO and DMF in patients with RRMS

Discover the results of the real-world Teri-RADAR study. Among other conclusions, the study shows that no differences were observed for lesion-based MRI measures of disease activity between AUBAGIO and DMF. However, favourable effects were observed for BVL with AUBAGIO.

Analysis: First-line disease-modifying therapies in patients with RRMS

Watch an analysis of first-line disease modifying therapies in patients with RRMS using the French nationwide health claims database from 2014—2017. The study concludes that teriflunomide showed higher treatment persistence vs. other DMTs but no difference in treatment, compliance or relapses compared to DMF.

The positive impact of AUBAGIO in the real world

Read a summary of key real-world data on Aubagio. Among other highlights, the data includes high treatment satisfaction scores that were seen across all TSQM domains in all patients, including those who switched to AUBAGIO (teriflunomide).

  1. Coyle PK, Khatri B, Edwards KR, et al; for the Teri-PRO Trial Group. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107-115.
  2. Coyle PK, Khatri B, Edwards KR, et al; for the Teri-PRO Trial Group. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: results from the global phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 2018;26:211-218.
  3. Vermersch P, Suchet L, Colamarino R, Laurendeau, Detournay B. An analysis of first-line disease-modifying therapies in patients with relapsingremitting multiple sclerosis using the French nationwide health claims database from 2014–2017. Mult Scler Relat Disord. 2020; 19;46:102521. doi: 10.1016/j.msard.2020.102521.
  4. Zivadinov R, Bergsland N, Carl E, et al. Effect of teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case-control pilot study. J Clin Med. 2019;8(3):344. doi:10.3390/jcm8030344.
  5. Laplaud D, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93(7):e635–e646.
  6. Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, et al. Comparative effectiveness of teriflunomideand dimethyl fumarate in patients withrelapsing forms of MS in the retrospectivereal-world Teri-RADAR study. J. Comp. Eff. Res.2019 Apr; 8(5) 305-3016.

MAT-XU-2302958 (v1.0) Date of Preparation: October 2023